The SARM1 targeting therapeutics market is projected to grow at a CAGR of 102.1%, during the period 2033-2040, claims Roots Analysis SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market share. Roots Analysis has announced the addition of “SARM1 Inhibitors Therapeutics Market , 2022 – 2040” report to its list of offerings. Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders across various preclinical studies and early stages of clinical development, worldwide. With the ongoing pace of innovation in this field, increasing R&D activity and promising pre-clinical data, several promising leads are anticipated to be commercially launched over the coming decade and SARM1 targeting therapeutics market is anticipated to witness substantial growth in the mid to long-term. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/sarm1-inhibitors-market/request-sample.html Key Market Insights Presently, several SARM1 targeting therapy candidates are being developed by various industry players About 65% of the pipeline candidates are currently being evaluated in the preclinical stages of development, followed by those currently in the discovery stage (35%). Further, it is worth mentioning that close to 85% of the SARM1 inhibitors are small molecules. Currently, a number of companies claim to be engaged in the development of SARM1 inhibitors The SARM1 inhibitors market is dominated by the presence of large companies (81%), followed by small players (19%). In addition, around 20% of the players were established post-2010. 120+ articles related to SARM1 inhibitors have been published between 2011 and 2022 Majority (81%) of the articles published in this domain were research papers, followed by review papers (12%). It is important to note that more than 70% of the total number of articles were published post-2018. Over 30 grants have been awarded for research related to SARM1 inhibitors, since 2014 Close to 40% of the total amount was awarded under the R01 mechanism (which supports research projects). Further, genetics and neurology emerged as the key research departments, having received 34% of the total grants, each. 70+ patents related to SARM1 targeting therapeutics have been filed / granted till 2022 Over the years, the number of patents filed for SARM1 inhibitors has increased gradually; majority of the patents have been filed / granted in 2021. Most of the patents in this domain are patent applications (96%), followed by granted patents (3%). North America is anticipated to capture more than 65% share of the market, by 2040 By 2040, the market revenues are likely to be driven by the sales of small molecules (95%) being developed as SARM1 inhibitors. Further, sales of therapeutics targeting multiple sclerosis are likely to contribute to a majority share (~40%) of revenues, in the long term. For additional details, please visit https://www.rootsanalysis.com/reports/sarm1-inhibitors-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. RNAi Market: Therapeutics and Technologies (Focus on siRNA, miRNA, shRNA and DNA) (3rd Edition): Industry Trends and Global Forecasts, 2022-2035 2. Global Therapeutic Vaccines Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com